We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Brain Cancer

Journal Scan / Research · August 18, 2022

Depatuxizumab Mafodotin in EGFR-Amplified Newly Diagnosed Glioblastoma



Additional Info

Disclosure statements are available on the authors' profiles:

Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial
Neuro-oncology 2022 Jul 15;[EPub Ahead of Print], AB Lassman, SL Pugh, TJC Wang, K Aldape, HK Gan, M Preusser, MA Vogelbaum, EP Sulman, M Won, P Zhang, G Moazami, MS Macsai, MR Gilbert, EE Bain, V Blot, PJ Ansell, S Samanta, MG Kundu, TS Armstrong, JS Wefel, C Seidel, FY de Vos, S Hsu, AF Cardona, G Lombardi, D Bentsion, RA Peterson, C Gedye, V Bourg, A Wick, WJ Curran, MP Mehta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading